I. Introduction to Recombinant Subunit Vaccines {#sec0001}
===============================================

Historically, vaccines have been one of the most cost‐effective and easily administered means of controlling infectious diseases in humans and animals. Vaccine development has its roots in the work of Edward Jenner (1749--1823) who discovered that man could be protected from smallpox by inoculation with cowpox ([@bib0074]) and the work of Louis Pasteur (1822--1895) who developed the first rabies vaccine ([@bib0078]). These pioneering efforts led to vaccines against diseases that had once claimed millions of lives worldwide ([@bib0006]). Childhood vaccination programs are now common practice and elaborate vaccination programs have been set up by the World Health Organization (WHO), leading to the official eradication of smallpox in 1979 ([@bib0074]). Today large parts of the world are also declared poliomyelitis free, and measles is the next target for eradication. Vaccines have controlled major bacterial and viral diseases in humans, and effective vaccines are available against many more ([@bib0006], [@bib0102]). Vaccination also protects our livestock and pet animals ([@bib0205]). For some diseases, however, such as malaria and acquired immunodeficiency syndrome (AIDS), vaccines are desparately sought.

Most human and animal vaccines are based on killed or live‐attenuated pathogens. Killed vaccines require the production of large amounts of often highly virulent pathogens and these types of vaccines are therefore risky to produce. Another risk lies in the potential for incomplete inactivation of the pathogens. Inactivation on the other hand affects the immunogenic properties of the pathogen, and hence the efficacy as a vaccine, and it is often difficult to find the balance between efficient inactivation and conservation of immunogenicity. Live‐attenuated vaccines consist of pathogens that are reduced in virulence or have been attenuated either by growing them in alternative hosts or under unfavorable growing conditions, or by recombinant DNA technology. These live‐attenuated vaccines can potentially replicate in their host, but are typically attenuated in their pathogenicity to avoid the development of severe disease. Live vaccines elicit humoral and cellular immunity, and may provide lifelong protection with a single or a few doses ([@bib0065], [@bib0102], [@bib0248]). Such long‐term protection is advantageous in developing countries where individuals are often only immunized once. A drawback of live‐attenuated vaccines is that they can cause side effects, which may be dangerous when used for prophylaxis in immunocompromised persons such as the elderly or individuals with genetic or acquired diseases of the immune system (e.g., AIDS or severe combined immunodeficiency; SCID). Live‐attenuated vaccines may also convert to virulent strains and spread to nonimmunized persons as observed during recent poliomyelitis outbreaks ([@bib0145]). Adverse effects with both killed and live‐attenuated vaccines can also be due to allergic reactions to components of the vaccine such as residual egg proteins in the case of influenza vaccines ([@bib0144]) or gelatin in the measles‐mumps‐rubella (MMR) vaccine ([@bib0206]).

The development of vaccines is not easy for all infectious diseases and the medical and veterinary world is challenged frequently by the emergence of novel diseases such as AIDS, severe acute respiratory syndrome (SARS), and *West Nile virus* infection. The vaccine industry is under constant pressure for rapidly changing pathogens, for which large amounts of vaccines are needed annually, such as influenza viruses ([@bib0203]), and flexible vaccine production techniques are required. For several infectious diseases vaccines cannot be developed using conventional approaches, for instance due to a lack of appropriate animal production systems or the high‐mutation frequency of the pathogen (*Human immunodeficiency virus* (HIV), malaria). A vaccine against the H5N1 influenza strain that is currently epidemic in Asian poultry could not be produced the classical way, by using embryonized chicken eggs without reducing the virulence of the virus by reverse genetics, due to high‐mortality rates of the chicken embryos ([@bib0116]).

Recombinant protein production systems may provide good alternatives for the development of vaccines that are more difficult to produce *in vivo* for manufacture of so‐called subunit vaccines. A pathogen consists of many proteins, frequently with carbohydrate moieties, but these are not all equally important for generation of an adequate immunological response. Subunit vaccines contain the immunodominant components of a pathogen and in the case of viral vaccines these are often (glyco)proteins of the viral coat or envelope such as the hepatitis B surface antigen ([@bib0026], [@bib0287]) or the classical swine fever virus (CSFV) E2 glycoprotein ([@bib0026], [@bib0287]). Viral coat proteins sometimes form virus‐like particles (VLPs) when expressed in heterologous systems ([@bib0035]), which are often immunogenic and may induce both humoral and cellular responses. The subunit vaccine against hepatitis B produced in yeast is highly succesful. An extreme example of subunit vaccines are peptide‐based vaccines which consist of small amino acid chains harboring the part of the antigenic protein that is recognized by antibodies. Typically, subunit vaccines do not contain the genetic material of the pathogen or only a small part thereof. Therefore, these vaccines cannot cause disease and do not introduce pathogens into nonendemic regions. An additional advantage of subunit vaccines is that they can be used in combination with specific marker tests, which make it possible to *d*ifferentiate *i*nfected from *v*accinated *a*nimals, the so‐called DIVA vaccines ([@bib0039], [@bib0294]); an important issue in monitoring virus prevalence and virus‐free export of animals and their products.

Immunogenic subunits can be isolated chemically from the pathogen, such as the purified capsular polysaccharides present in the *Streptococcus pneumonia* vaccine (Pneumovax23; Merck). This process still requires the production of virulent pathogens, which is not without risk. An alternative is the use of recombinant DNA technology to produce protein subunits in a heterologous system, and a variety of expression systems are available ([@bib0047], [@bib0102]). The yeast system *Saccharomyces cerevisiae* for instance is used to produce the hepatitis B subunit vaccine ([@bib0287]), which is currently the only licensed recombinant subunit vaccine for human use. The yeast *Pichia pastoris* is used for production of the antitick vaccine Gavac™ ([@bib0038]), which protects cattle against the tick *Boophilus microplus*, the transmitter of *Babesia* and *Anaplasma* parasite species. Insect cells are used to produce vaccines against classical swine fever or hog cholera ([@bib0063], [@bib0288]). For the production of recombinant proteins in higher eukaryotics, mammalian, insect, and plant expression systems are available that either use trangenes or viral vectors for protein expression. Plants have been recognized for the production of so‐called edible subunit vaccines to be administered by ingestion of vegetable foods ([@bib0176], [@bib0266]).

This chapter concentrates on the use of cultured insect cells or larvae in combination with baculovirus expression vectors for the production of subunit vaccines. The baculovirus expression system is an accepted and well‐developed system for the production of viral antigens with vaccine potential ([@bib0065], [@bib0101], [@bib0300]). This system has also been explored for development of vaccines against protozoan parasites ([@bib0136]) and for therapeutic vaccines against tumors. A vaccine against prostate‐cancer (Provenge) is in phase II/III clinical trials and is based on combining recombinant prostatic acid phosphatase (characteristic of 95% of prostate cancers) with the patient\'s own dendritic cells before immunization ([@bib0018], [@bib0235]). Trials have also been initiated for a prophylactic vaccine using VLPs produced in insect cells against cervical cancer caused by *Human papillomavirus* (HPV) *16* ([@bib0178]).

Each expression system has advantages and drawbacks ([Table I](#tbl0001){ref-type="table"} ) and the system of choice depends very much on the specific requirements for a particular vaccine and is often based, at least partly, on trial and error. Before a definitive choice can be made, the expression levels achieved, the adequacy of posttranslational modifications, the immunological performance, the possibilites for scale‐up, the costs, the risk of contamination, the method of administration, and legal aspects must all be taken into account.Table IPotential of Various Expression Systems for Recombinant Subunit Vaccine Production[a](#tblfn0001){ref-type="table-fn"}Processing/feature*E. coli*YeastMammalian cellsInsect cellsPlantsGlycosylation−++ + ++ ++Phosphorylation−++ ++ ++Acylation−++++Amidation−−++−Proteolysis+/−+/−+++Folding+/−+/−+ + ++ ++Secretion+/−++ ++ ++/−Serum freeNot relevantNot relevant++Not relevantYield (%dry mass)1--51\<1Up to 30\<5Scale‐up+ + ++ + ++++ + +Downstream processing+++ +++− −CostsLowLowHighIntermediateLowSafety+ ++ +++ ++ +Versatility+++ ++ + ++[^1]

II. The Baculovirus--Insect Cell Expression System for Vaccine Production {#sec0002}
=========================================================================

A. Characteristics {#sec0003}
------------------

The baculovirus--insect cell expression system ([@bib0260]) has been developed for the production of biologically active (glyco)proteins in a well‐established and safe eukaryotic environment ([@bib0153]). The family *Baculoviridae* contains rod‐shaped, invertebrate‐infecting viruses, which have large double‐stranded, covalently closed circular DNA genomes ([Table II](#tbl0002){ref-type="table"} ). The members of this large virus family are taxonomically divided into the genera Nucleopolyhedrovirus (NPV) and Granulovirus (GV), based on occlusion body morphology ([@bib0276]). NPVs express two genes, *polyhedrin* and *p10*, at very high levels in the very late phase of infection. The polyhedrin protein forms the viral occlusion bodies or polyhedra and p10 is present in fibrillar structures, which function in polyhedron morphology and in breakdown of infected cell‐nuclei to release the polyhedra ([@bib0197], [@bib0292]). These two genes are not essential for virus replication in cell culture and, therefore, their promoters are exploited to drive foreign gene expression, which forms the basis for the baculovirus--insect cell expression system. Since baculoviruses are rod‐shaped, large amounts of foreign DNA can be accommodated within the virus particle, in contrast to vaccinia and especially adenovirus expression vectors ([Table II](#tbl0002){ref-type="table"}).Table IICharacteristics of Baculovirus Vectors Versus Vaccinia and Adenovirus Vectors[a](#tblfn0002){ref-type="table-fn"}FeatureBaculovirus[b](#tblfn0003){ref-type="table-fn"}AdenovirusVacciniaVirus morphologyEnveloped, rod shapedNonenveloped, icosahedralBrick shapedGenome structureCircular dsDNALinear dsDNALinear dsDNAGenome size130 kbp±35 kbp190 kbpExpandabilityLargeLowIntermediateParticle dimensions30−60 × 250−300 nm80--110 nm250 × 250 × 200 nmReplication siteNucleusNucleusCytoplasmReplication in humansNoneReplication competent or defectiveYesProgeny virusBudding BVs/lysis ODVsAccumulation in the nucleusExocytosis/lysisPathogenicity for mammals including humansNonpathogenicLow due to host defense and attenuationReduced with modified strainsImmunological complicationsComplement inactivationStrong protective responses of the host--Immunological history--Preexisting immunity due to natural infectionsPreexisting immunity due to smallpox vaccinationProtein production system in cell linesYesLess frequentlyYesApplications: Antigen display vectorSurface display vectorsNoNo Carrier DNA vaccine vectorYesYesYes Gene therapy++ +−Vaccine examplesTherapeutic prostate cancer vaccine (see text for further information)Immunomodulators, therapeutic cancer vaccinesMucosal immunity against tuberculosis and HIV[^2][^3]

The type member of the NPVs is *Autographa californica* multiple nucleopolyhedrovirus (AcMNPV), a virus with a genome of 133 kilobase pairs ([@bib0010]). This baculovirus is routinely used for foreign gene expression. The baculovirus *Bombyx mori* NPV is being used for vaccine purposes to a much lesser extent ([@bib0044], [@bib0190]). Baculovirus expression vectors replicate in cultured insect cells or larvae and high yields of heterologous protein are generally obtained when the strong viral *polyhedrin* and *p10* promoters are exploited ([@bib0147], [@bib0195]). The insect cell lines used in the baculovirus expression system are derived from lepidopteran insects (moths) and are most often *Spodoptera frugiperda* lines (Sf9 or Sf21) and *Trichoplusia ni* (High Five™) cells, which can be used in combination with AcMNPV‐based vectors. *B. mori* cells (e.g., Bm5) are used for BmNPV. Insect cell lines vary in their characteristics in terms of growth rate, protein production, secretion efficiency and glycosylation pattern, and interference with viral genome stability ([@bib0218], [@bib0302]). These insect cells are relatively easy to maintain and many grow equally well in suspension in large volumes (up to 2000 L reactions) and at high densities as on solid supports, and can be cultivated in serum‐free media which facilitates purification of recombinant proteins. Unlike mammalian cells, they do not require CO~2~ and can easily withstand temperature fluctuations. An extra advantage is that the chance of contamination with human or mammalian viruses, especially in serum‐free cultures, is small compared to mammalian production systems because these vertebrate viruses do not replicate in lepidopteran cells. These cells do not support the growth of mammalian mycoplasmas either. Instead of insect cells, whole insect larvae may be used as live bioreactors for vaccine production. The use of whole insect larvae has the advantage that the simple insect‐rearing technology and downstream processing can be exploited. Such *in vivo* production could be performed by small‐scale local industries, especially if the larvae can be fed directly to animals such as for an experimental Newcastle disease vaccine for chickens ([@bib0190]). Such vaccines are less well defined however and quality control may therefore be more difficult to achieve.

Expression of proteins in insect cells allows for appropriate folding, posttranslational modification, and oligomerization and therefore, biological activity is normally preserved. Protein glycosylation in insects and mammals is not identical though: the *N*‐glycan--processing pathway in insects results in glycoproteins with paucimannose glycan groups, in contrast to mammalian glycoproteins which contain complex sialylated glycans (see also Harrison, this volume, pp. 159--191). The exact glycan composition varies between different insect cell lines ([@bib0153], [@bib0279]). In general, glycan groups are not very immunogenic and therefore this does not seem to be a major disadvantage for subunit vaccines. In situations where more authentic glycosylation is required, for instance for preserving functional activity, transformed "humanized" insect cell lines expressing mammalian glycosylation enzymes are available ([@bib0127], [@bib0153], [@bib0279]). For some insect cell lines it has been reported that fucose groups are added to *N*‐glycans. The impact of this remains to be determined, but since fucans may cause allergic reactions, it may be a point for consideration when choosing an insect cell line for vaccine production ([@bib0168], [@bib0279]).

B. Baculovirus Vectors {#sec0004}
----------------------

Originally, the baculovirus expression system was based on the allelic exchange of the baculovirus polyhedrin gene for a heterologous gene by recombination in insect cells ([@bib0260]). In a similar way, baculovirus vectors have since been developed which exploit the nonessential very late baculovirus *p10* promoter ([@bib0301], [@bib0308]). Vectors that leave the polyhedrin gene intact can be used for the production of recombinant proteins in insect larvae ([Fig. 1](#fig0001){ref-type="fig"} ). The *in vivo* recombination protocol was improved by using linearized viral DNA in the allelic replacement, which resulted in dominant selection and much higher percentages of recombinant viruses ([@bib0149], [@bib0180]). In vectors of this type (BacPAK™ vectors, BaculoGold™, Bac‐N‐Blue™) the linearized viral DNA carries a lethal deletion (ORF1609) and becomes replication competent only after recombination with a transfer plasmid carrying the foreign gene, thereby restoring the deletion ([@bib0150]). Baculovirus vectors based on Gateway technology (BaculoDirect™) are linear baculovirus vectors in which foreign genes are introduced through site‐specific *in vitro* recombination.Fig 1Flow chart showing four different methods to make a vaccine based on your favorite gene (*YFG*) in the baculovirus expression system: (1) protein expression in insect cell bioreactors using the *polyhedrin* locus for expression, (2) protein expression in insect larvae leaving the *polyhedrin* gene intact; expression is driven either by a duplicated *p10* promoter or by the original *p10* promoter, (3) baculovirus surface display methods where YFG is fused to GP64, and (4) DNA vectors with a mammalian promoter (*mp*) for synthesis of your favorite gene product (YFGP) in the target species. Subsequent steps in the process are: (A) selection and PCR amplification of *YFG*, (B) cloning into the appropriate baculovirus vector, (C) generation of recombinant BV particles or occlusion bodies, (D) production in insect cells in bioreactors or larvae, (E) purification of recombinant YFGP or collection of BVs loaded with either YFGP or YFG, and (F) delivery of prophylactic or therapeutic vaccines.

At about the same time, another efficient and rapid method for generation of recombinant baculoviruses was developed ([@bib0172]) that employed transposition of a foreign gene expression cassette from a donor plasmid into a bacterial artificial chromosome (BAC) which contains the entire AcMNPV genome (bacmid). In this system (Bac‐to‐Bac™) recombinant baculovirus genomes are generated in *Escherichia coli* and then used to transfect insect cells to obtain recombinant baculovirus particles. After generating high‐titer virus stocks, insect cells are infected to produce recombinant proteins. With the bacmid‐based methodology the time to generate recombinant viruses is reduced considerably. Another advantage is that the recombinant bacmid can be stored in *E. coli* and recovered when needed. A disadvantage is that the bacterial gene cassette present in bacmid‐derived viruses may easily be lost during virus passaging ([@bib0217]). In addition to AcMNPV, bacmids have also been constructed for *Spodoptera exigua* MNPV and *Helicoverpa armigera* SNPV ([@bib0216], [@bib0303]). The most recent method combines bacmid technologies with allelic replacement (FlashBac™; Oxford Expression Technologies) and thereby removes the BAC sequences from the viral genome. This latter system is especially suitable for high‐throughput screening.

Over the years, novel baculovirus vectors have been developed with special features and for more specific applications: transfer vectors have been modified to express polyhistidine‐tagged proteins for easy purification (pFastBac‐His™). Transfer vectors with dual, triple, or quadruple promoters usually *p10* and *polyhedrin*, have been developed for allelic replacement ([@bib0019], [@bib0308]); dual (pFastBacDual™) and quadruple vectors ([@bib0271]) have also been developed for bacmid technology. Such multiple vectors can be used to express various proteins simultaneously, and hence are useful for producing multimeric complexes, including viral capsids consisting of more than one viral protein ([@bib0019]). Balancing expression levels is sometimes a problem in these vectors and may require coinfection with a vector expressing only the dominant protein, or a modification of the promoters. One of the promoters in multiple promoter vectors may be used to express a reporter gene, such as green fluorescent protein (GFP), which makes it easy to follow the infection process in cells, perform virus titrations, and track baculovirus infection in the insect ([@bib0041], [@bib0133]). The recently developed vector system (UltraBac) uses the baculovirus late basic protein (P6.9) promoter to express GFP together with the foreign gene to allow earlier monitoring of infection ([@bib0214]).

Baculovirus surface display vectors ([@bib0094]) expose the antigen on the surface of budded baculovirus particles. This is achieved by fusing the foreign antigen to the baculovirus envelope glycoprotein GP64 ([@bib0188]). The chimeric protein is transported to the cell membrane and is taken up in the viral envelope during budding. This system has also been combined with bacmid technology ([@bib0133]). The recombinant budded virus (BV) particles and lysates of cells infected with a display vector have been shown to evoke protective immune responses ([@bib0136], [@bib0269], [@bib0318]). Baculovirus vectors that express foreign genes in fusion with polyhedrin along with wild‐type polyhedrin allow for incorporation of antigens into baculovirus occlusion bodies ([@bib0128]). These occlusion bodies are stable and easy to purify and can be used directly for immunization ([@bib0312]).

C. Adaptations for Secreted Proteins {#sec0005}
------------------------------------

Expression of surface (glyco)proteins that go through the export pathway is in general more difficult than expression of soluble cytoplasmic proteins and results in much lower yields ([@bib0293]). To increase the production level, surface proteins are often expressed as secreted proteins by removing hydrophobic transmembrane regions (TMR) that serve to anchor the protein to cell membranes. Removing these domains by recombinant DNA technology leads to secreted proteins which can then be purified from the culture medium. However, some caution is needed because this approach may affect folding and vaccine efficacy.

Not all proteins present at the surface under native conditions are automatically transported to the cell surface when expressed in insect cells, such as the p67 surface protein of the bovine parasite *Theileria parva* ([@bib0193]). When the original signal peptide was replaced with an insect analogue, such as the honeybee mellitin signal peptide ([@bib0275]), p67 was properly routed to the cell surface ([@bib0134]). A similar routing of p67 to the export pathway could be obtained by fusion to GP64 in a surface display vector ([@bib0132]), where the GP64 signal peptide directed the protein to the cell surface.

Membrane and secreted proteins pass through the endoplasmic reticulum (ER) and the Golgi apparatus on their way to the cell surface and may become glycosylated during this process. The abundant baculovirus protein chitinase is also transported to the ER and accumulates there due to a KDEL retention sequence ([@bib0246], [@bib0277]). Chitinase is expressed in the late phase of baculovirus infection and is involved in the dissolution of the insect chitinous cuticle to enhance the spread of viral occlusion bodies ([@bib0106]). Deletion of chitinase from the baculovirus vector resulted in higher levels of secreted recombinant protein ([@bib0225]) possibly because chitinase "cloggs up" the protein translocation machinery and competes with recombinant secretory proteins. The FlashBac system described earlier lacks this chitinase gene. Another baculovirus protein, v‐cathepsin also accumulates in the ER and is activated on cell death by proteolytic cleavage ([@bib0113]). Processing of pro‐v‐cathepsin into active cathepsin is also triggered by chaotropic agents, such as sodium dodecyl sulfate, and this may result in proteolysis of recombinant proteins during extraction and purification ([@bib0114]). A bacmid vector that lacked both chitinase and v‐cathepsin (AcBacΔCC) improved the stability of a secreted recombinant protein, thereby increasing the yield of full‐length protein molecules ([@bib0134]).

Folding of complicated transmembrane glycoproteins can be improved by coexpression of molecular chaperones. The serotonin transporter (SERT) protein is a brain glycoprotein with 12 predicted transmembrane domains. Coexpression of the chaperones calnexin and, to a lesser extent, of immunoglobulin heavy chain‐binding protein (BiP) or calreticulin increased the yield of functional SERT threefold. The foldase ERp57 did not have this effect ([@bib0272]). Calreticulin and calnexin were also shown to increase the level of active lipoprotein lipase when coexpressed in insect cells, and to stimulate dimerization of the recombinant protein ([@bib0320]). Expression of calnexin and calreticulin in a stable transgenic insect cell line, which was than infected with a recombinant baculovirus, resulted in a lower ratio of secreted versus intracellular recombinant protein than when cells were coinfected with two baculoviruses, one carrying the gene of interest and the other a chaperone ([@bib0139]). This result suggests that chaperone expression levels should be of the same order as recombinant protein levels.

D. Baculovirus Vectors with Mammalian Promoters {#sec0006}
-----------------------------------------------

Another special adaptation is the incorporation of mammalian promoters in baculovirus vectors to drive foreign gene expression. Baculovirus vectors with mammalian promoters (BacMam™ viruses) have the potential to serve as gene delivery vectors in gene therapy ([@bib0121], [@bib0152]) and have also been tested for vaccination purposes ([@bib0002], [@bib0007], [@bib0072], [@bib0224]). In this case, a mammalian promoter or a viral promoter active in mammalian cells, such as the human cytomegalovirus (HCMV) IE1 promoter, drives intracellular expression of the antigen. Exposure on the cell surface via the major histocompatibility complex (MHC) activates the cellular immune system and in this respect, these types of vaccines resemble DNA vaccines. BacMam™ vectors are produced in insect cells and are replication incompetent in mammalian cells ([Table II](#tbl0002){ref-type="table"}). A further advantage is that multiple genes can be inserted simultaneously into the baculovirus genome allowing for multivalent vaccines. Expression of multiple proteins is an advantage of the baculovirus expression system over other systems, especially adenovirus vectors, where the maximal increase in genome size is more limited due to packaging restrictions.

E. Adaptations for Vector Genome Stability {#sec0007}
------------------------------------------

For manufacturing subunit vaccines, large‐scale production units will be needed, for instance for the production of malaria or the annual influenza subunit vaccines. Baculovirus--insect cell systems have been scaled‐up to large‐scale cultures in either fermentors (bioreactors) or cellbag devices (WAVE reactors). Insect cell bioreactors up to 2000 L have been reported. The bioprocess technology behind this large scale production has been reviewed by others ([@bib0120], [@bib0124], [@bib0302]). A problem repeatedly encountered when expressing recombinant proteins with baculovirus vectors is a drop in expression levels with increasing virus passage (reviewed in [@bib0154]). This so‐called "passage effect" is intrinsic to baculovirus replication in cell culture, but is less critical for small laboratory‐scale protein production when the number of virus passages is low (\<10). It is a significant problem though for large‐scale industrial production of vaccines in insect cell bioreactors ([@bib9005]) and prevents the use of continous bioreactors. The major causes of loss of recombinant protein expression are (1) mutations in the *FP25K* gene, reducing the activity of the *polyhedrin* promoter ([@bib0104]), (2) the generation of defective interfering particles (DIs) which replicate at the expense of the full‐length recombinant virus ([@bib9001], [@bib0215], [@bib0310]), (3) the intracellular accumulation of concatenated viral sequences, for example, non‐*hr* (homologous repeat) origins of DNA replication) which interfere with replication of full‐length genomes ([@bib9002], [@bib0216]), and (4) spontaneous deletion of the heterologous gene from the baculovirus vector. The latter aspect is especially seen in bacmid‐derived vectors, which are extremely sensitive to spontaneous removal of the expression cassette, a large piece of DNA which is not under selection ([@bib0217]). To prevent the amplification of DIs, baculovirus vectors must be used at low multiplicities of infection (MOI) ([@bib0059], [@bib0310]) and it is now common practice to keep the number of viral passages to a minimum and establish low‐passage virus banks as seed stocks for production purposes.

In recent years, several approaches have been used to improve the stability of the baculovirus genome. The accumulation of non*‐hr*--containing sequences can easily be prevented by removing this sequence from the baculovirus backbone ([@bib0216]). Reducing the distance between origins of replication in the bacmid system by insertion of an extra *hr* sequence within the expression cassette also resulted in prolonged foreign gene expression in a test bioreactor ([@bib0219]). In the FlashBac system, all destabilizing bacterially derived sequences are removed on recombination with the transfer vector. To prevent loss of the foreign gene cassette, a bicistronic vector was developed that contained the foreign gene and the baculovirus essential gene *GP64* on a single bicistronic transcriptional unit linked by an internal ribosome entry site (IRES). *GP64* was deleted from its original locus. In this bicistronic vector, loss of the foreign gene would automatically result in loss of expression of the essential gene, which is needed for the generation of complete virus particles as well as for DIs. GFP expression levels were kept at a high level for at least 20 passages with this vector providing dominant selection for GP64 ([@bib9003]). This system awaits testing for expression of proteins of medical importance. By combining several of the methods described in this section, it is likely that genome stability will be further improved.

III. Viral Subunits Expressed in the Baculovirus System {#sec0008}
=======================================================

Since its recognition as a production system for subunit vaccines ([@bib0300]), the baculovirus--insect cell expression system has been used extensively for the expression of candidate vaccine antigens. A comprehensive overview of the viral antigens from viruses of vertebrates that have been expressed in this system is provided in [Table III](#tbl0003){ref-type="table"} . Only those antigens that were tested for their ability to induce protective immune responses are included. In addition, many viral antigens have successfully been expressed in insect cells for the development of diagnostics, and to perform structural and functional studies, but these studies are excluded from this chapter. Various viral antigens ranging from capsid and envelope proteins to nonstructural proteins have been chosen for the development of subunit vaccines. These viral antigens can be divided into those that are expressed as single or oligomeric protein subunits, and those that self‐assemble into VLPs. Different approaches to vaccination are described in the examples later, with special attention paid to influenza subunit vaccines.Table IIIVertebrate Immune Response Studies with Viral Proteins Expressed in the Baculovirus--Insect Cell System[a](#tblfn0004){ref-type="table-fn"}Virus family or genusAbbreviationHostAntigen(s)[b](#tblfn0005){ref-type="table-fn"}Neutralizing antibodies[c](#tblfn0006){ref-type="table-fn"}T cells/cytokinesProtection host/modelReferences***Asfarviridae****African swine fever virus*ASFVPigsp22, p30, p54, p72Yes--No[@bib0192]p30--p54 fusionYes--Yes[@bib0016]HAYes--Yes[@bib0242]***Arenaviridae****Lymphocytic choriomeningitis virus*LCMVHumans, rodentsGP, NP--T cellsYes[@bib0011]***Arteriviridae****Porcine reproductive and respiratory syndrome virus*PRRSVPigs3, 5 (7)Yes--Yes[@bib0223]***Birnaviridae****Infectious pancreatic necrosis virus*IPNVFishStructural proteins (VLP[d](#tblfn0007){ref-type="table-fn"})----Partial[@bib0256]*Infectious bursal disease virus*IBDVBirdsVP2 (VLP)Yes--Yes[@bib0220], [@bib0304]VP2 (VLP), VPX, PPYes--Yes[@bib0183]VP2 + VP3 + VP4 (chimeric)Yes--Yes[@bib0261]VP2 + VP3 + VP4Yes--Yes[@bib0285]VP3No--No[@bib0221]*Yellowtail ascites virus*YAVFishVP2, VP3, NSYes--Yes[@bib0245]***Bunyaviridae****La Crosse virus*LACVHumansG1Yes--Yes[@bib0210]*Hantaan virus*HTNVHumans, rodentsG1, G2, NPYes--Yes[@bib0251]*Rift Valley fever virus*RVFVHumans, ruminantsG1, G2Yes--Yes[@bib0250]***Caliciviridae****Hepatitis E virus*HEVHumansCapsid (VLP)Yes--Yes[@bib0164], [@bib0165]*Norwalk virus*, Genogroup INWVHumansCapsid (VLP)Antibodies----[@bib0012], [@bib0013], [@bib0014], [@bib0098]*Norwalk virus*, Genogroup IINWVHumansCapsid (VLP)AntibodiesYes--[@bib0194]***Circoviridae****Chicken anaemia virus*CAVBirdsVP1, VP2Yes--Yes[@bib0151]*Porcine circovirus 2*PCV2PigsORF2Yes--Yes[@bib0023]***Coronaviridae****Avian infectious bronchitis virus*IBVChickenS1Yes--Partial[@bib0040], [@bib0262]*Feline infectious peritonitis virus*FIPVCatsNNoYesYes[@bib0111]*SARS corona virus*SARSHumansSpike GPYes--Yes[@bib0022]*Transmissible gastroenteritis virus*TGEVPigsS + N + MYesYesPartial[@bib0253]***Deltavirus****Hepatitis deltavirus*--Humans/rodentsHD AgNo----[@bib0138]HD Ag p24, p27Antibodies--No[@bib0075]***Filoviridae****Ebola virus*EBOVHumansGPYesT cellsPartial[@bib0187]*Marburg virus*MBGVHumansGPYes--Yes[@bib0109]***Flaviviridae****Bovine viral diarrhea virus*BVDVCowsE2Yes--Yes[@bib0024]*Classical swine fever virus*CSFVPigsE2Yes--Yes[@bib0004], [@bib0026], [@bib0119]*Dengue 2 virus*DEN 2HumansEYes----[@bib0143]EYes--Partial[@bib0062], [@bib0298]ENo--Partial[@bib0073]NS1Yes--Partial[@bib0230]*Dengue 4 virus*DEN 4HumansCocktailYes--Yes[@bib0321]Cocktail, EYes--Partial[@bib0071]*Dengue virus 2 + 3*DEN2/3HumansE protein hybridYesT cells--[@bib0020]*Japanese encephalitis virus*JEVprME, E, NS1Yes--Yes/No[@bib0315]E, NS1Yes--Yes[@bib0185]*West Nile virus*WNVHumans/birdsprME (VLP)Yes--Yes[@bib0229]*Hepatitis C virus*HCVHumansE1 + E2 (VLP)YesT cells/cytokinesYes[@bib0129]*St Louis encephalitis virus*SLEVHumansprMEYes--Yes[@bib0299]*Tick‐borne encaphalitis virus*TBEVHumansE, C--T cells/ cytokines--[@bib0091]*Yellow fever virus*YFVHumansE, E + NS1Yes--Yes[@bib0066]***Hepadnaviridae****Hepatitis B virus*HBVHumansHBsAgAntibodies----[@bib0009]***Herpesviridae****Bovine herpesvirus 1*BHV‐1CowsgIIIYes----[@bib0198]gIVYes--Yes[@bib0290], [@bib0291]*Canine herpesvirus*CHVDogsgCYes----[@bib0314]*Equine herpesvirus 1*EHV‐1HorsesgBYes--Yes[@bib0156]gB, gC, gDYes/NoT cellsYes/No[@bib0202]gCYesT cellsYes[@bib0263]gC, gDYesT cellsYes[@bib0309]gDYes----[@bib0076]gD (DNA prime)YesT cellsYes[@bib0241]gD, gHYes/No--Yes/No[@bib0265]gH, gL----Partial/No[@bib0264]*Feline herpes virus 1*FHV‐1CatsgDYes----[@bib0177]*Guinea pig cytomegalovirus*GPCMVRodentsgBYes--Yes[@bib0249]*Herpes simpex virus 1*HSV‐1HumansgDYesT cellsYes[@bib0155]gEYes----[@bib0166]gB‐gI cocktailYes--Yes[@bib0087]gDYes--Yes[@bib0084]gD, gG, gK--Cytokines--[@bib0088]gEYesT cells/cytokinesYes[@bib0086]gKNo--ADE[e](#tblfn0008){ref-type="table-fn"}[@bib0089]gLNo--No[@bib0085]*Human cytomegalovirus*HCMVHumansgBYes----[@bib0179]IE1‐pp65--T cells--[@bib0297]*Phocid herpes virus 1*PhHV‐1SealsgBYes--Yes[@bib0103]*Pseudorabies virus*PrVPigsgIIYes--Yes[@bib0313]gIIIYes----[@bib0125]***Orthomyxoviridae****Equine influenza virus*H3N8HorsesH3No--Partial[@bib0200]*Human influenza A*H1N1HumansH1 (proteosomes)Yes--Yes[@bib0131]H2N2M2Yes--Yes[@bib0259]H3N2H3 + M1 (VLP)Yes--Yes[@bib0082]H3N2H3YesYesYes[@bib0226], [@bib0227]H3N2H3Yes----[@bib0281]H3N2H3, N2Yes--Yes[@bib0030], [@bib0130]H3N2N2Yes--Yes[@bib0064]H6N2N2Yes--Yes[@bib0146]MultipleH1, H3Yes----[@bib0157]*Avian influenza virus*H5N1BirdsH5No/----Yes[@bib0140], [@bib0267]H5N1H5In humans----[@bib0282]MultipleH5, H7YesYes[@bib0056]***Papovaviridae****Bovine papillomavirus*BPVCowsL1Yes----[@bib0148]*Cottontail rabbit papillomavirus*CRPVRodentsL1 (VLP)Yes--Yes[@bib0029], [@bib0046]L1, L1 + L2 (VLP)Yes--Yes*Human papillomavirus 16*HPV‐16HumansL1 (VLP)Yes----[@bib0105]L1 + L2 + E7 (VLP)Yes--Yes[@bib0096]L1 (VLP)--Yes--[@bib0070]***Paramyxoviridae****Bovine parainfluenza virus*BPIV‐3CattleHNYes--Yes[@bib0099]*Bovine repiratoiry syncytial virus*BRSVCattleFYesYesYes[@bib0254]F partialYesYesYes[@bib0307]*Human parainfluenza virus*HPIV‐3HumansFLow--Partial[@bib0100]FYes--Yes[@bib0232]HNYes--Yes[@bib0296]HN (+ RSV F)Yes--Yes[@bib0069], [@bib0115]HN‐F fusionYes--Yes[@bib0032]HN, F, HN‐FYes--Yes[@bib0161]*Human respiratory syncytial virus*HRSVHumansF (+HPIV‐HN)Yes--Yes[@bib0069], [@bib0115]FG fusionLow--Partial[@bib0051]FG fusionYes--Yes[@bib0031], [@bib0196], [@bib0305]*Newcastle disease virus*NDVBirdsF----Yes[@bib0190]HNYes--Yes[@bib0191]*Peste‐des‐petits‐ruminants virus*PPRVRuminantsHNYesYes--[@bib0257]*Rinderpest virus*RPVCowsF, HYes--No[@bib0017]H--Yes--[@bib0258]*Rubella virus*RVHumansE2, C----No[@bib0057]***Parvoviridae****B19 virus*B19VHumansVP1, VP2 (VLP)Yes----[@bib0137]*Canine parvovirus*CPVDogsVP2 (VLP)Yes--Yes[@bib0169], [@bib0244]*Duck parvovirus*DPVBirdsVP1, VP2 (VLP)Yes----[@bib0159]*Mink enteritis parvovius*MEVMinkVP2 (VLP)Yes--Yes[@bib0045]*Porcine parvovirus*PPVPigsVP2 (VLP)Antibodies----[@bib0182]***Picornaviridae****Foot‐and‐mouth disease virus*FMDVCattleEpitopes fused to GP64Yes--Yes[@bib0269]P1--2A + part P2----Partial[@bib0097]*Hepatitis A virus*HAVHumanspolyproteinYes----[@bib0236]***Polyomaviridae****Simian virus 40*SV40PrimatesLarge TAntibodies--Yes[@bib0255]YesNoYes[@bib0033], [@bib0306]***Reoviridae****African horse sickness virus*AHSVHorsesVP2 (VLP)----Yes[@bib0239]*Bluetongue virus*BTVSheep, cattleVP2 (VLP)Yes--Yes[@bib0240]VP2, VP5 (VLP)Yes----[@bib0170]VP2, VP5, VP3, and VP7 (VLP)Yes--Yes[@bib0077], [@bib0208], [@bib0238], [@bib0289]*Bovine rotavirus*BoRVCowsVP2 + VP4 + VP6 +Yes--Yes[@bib0049], [@bib0050]VP7 (VLP)*Human rotavirus*HRVHumansVP2 + VP4 + VP6 +Yes--Yes[@bib0049]VP7 (VLP)*Simian rotavirus*SiRVPrimatesVP2 + VP4 + VP6 +Yes--Yes[@bib0049], [@bib0050]VP7 (VLP)***Retroviridae****Feline immunodeficiency virus*FIVCatsgp120Yes--Partial[@bib0162]*Human immunodeficiency virus*HIV‐1Humansp24--T cells--[@bib0080]gp41 MEPR[f](#tblfn0009){ref-type="table-fn"}/ PERV[g](#tblfn0010){ref-type="table-fn"} p15E fusionYes----[@bib0175]gp41 + V3 loopYes----[@bib0174]gp55 (VLP)Boost----[@bib0126]gp55--gp120 (VLP)Yes----[@bib0008]YesT cells--[@bib0037], [@bib0278]gp120Antibodies----[@bib0209]No----[@bib0034]--No CTL--[@bib0211]--CTL--[@bib0067]gp160Partial----[@bib0142]No----[@bib0005]Boost[h](#tblfn0011){ref-type="table-fn"}----[@bib0093], [@bib0095], [@bib0171], [@bib0189]Boost, partialCTL--[@bib0052]AntibodiesT cells--[@bib0173]Memory B cells----[@bib0234]NoT cells--[@bib0186]HIV‐1Humansgp160--T cells--[@bib0092], [@bib0141]HIV‐2Humansgp41 HIV‐1 + HIV‐2 V3 loopYes----[@bib0174]*Simian immunodeficiency virus*SIVPrimatesEnv on gag VLPYesYes--[@bib0316], [@bib0317]gp160Boost--Yes[@bib0118]***Rhabdoviridae****Rabies virus*RABVMammalsGYesYesYes[@bib0228]GYes--Yes[@bib0079]N, GYes--Yes[@bib0068]*Mokola virus*MOKVMammalsGAntibodies--Yes[@bib0280][^4][^5][^6][^7][^8][^9][^10][^11]

A. Viral Envelope Proteins {#sec0009}
--------------------------

Envelope proteins are synthesized as single or oligomeric subunits. The expressed envelope proteins are often functionally active and have been reported to oligomerize, an indication that they are correctly folded ([@bib0056]). Commonly, viral envelope glycoproteins are glycosylated in insect cells. Examples of baculovirus‐produced subunit vaccine candidates ([Table III](#tbl0003){ref-type="table"}) are the fusion proteins and hemagglutinins of paramyxoviruses, such as *Newcastle disease virus*, and the E proteins of *Flaviviridae,* including *West Nile virus*, dengue viruses, and CSFV. Two commercially available veterinary subunit vaccines against classical swine fever (BAYOVAC CSF E2™ and PORCILIS PESTI™) are based on the CSFV E2 glycoprotein produced in insect cells ([@bib0004], [@bib0026], [@bib0027], [@bib0063], [@bib0288]). The E2 envelope glycoprotein of CSFV was expressed as a secreted protein by removing the TMR and this resulted in a threefold increase in expression levels, and allowed for purification of E2 from the culture medium ([@bib0119]). In a similar way, the related *Bovine diarrhea virus* (BVDV) E2 protein was expressed in insect cells ([@bib0024]). Recent research showed that the BVDV E2 protein needs to be glycosylated to be effectively secreted from baculovirus‐infected cells ([@bib0204]) and that the glycosylated protein was able to block BVDV infection better in an *in vitro* assay. Whether the glycosylated E2 protein also performs better as a vaccine is not known. The spike glycoprotein of the SARS coronavirus is one of the most recently expressed proteins in insect cells and protected mice against intranasal SARS infection ([@bib0022]).

Influenza presents a serious risk for both human and animal health. The single‐stranded RNA of the influenza virus changes quickly through an accumulation of mutations and frequent recombination events, requiring annual vaccine updates ([@bib0203]). The most threatening recent example is the outbreak of avian influenza of the H5N1 serotype which has killed birds and humans in the Far East since 2003 (WHO) and which caused the first human casualties outside this area in East Turkey in January 2006. The big fear is that such an avian virus will change into a virus that can be transmitted directly from man to man, which may then lead to an influenza outbreak of pandemic dimensions ([@bib0203]). The most widely used influenza vaccines, e g., Fluzone (Sanofi Pasteur) and Fluvirin (Chiron), consist of chemically inactivated split virus or purified virus subunits. These vaccines have several disadvantages which have recently been reviewed ([@bib0054], [@bib0055]), including reduced efficacy in the elderly, where vaccination does reduce mortality rates but is not very effective in preventing disease. In addition, an enormous number of eggs are needed each year (one egg per dose) which will very likely lead to a shortage of vaccine in the event of a pandemic; some strains grow poorly in eggs requiring coinfections with other strains or genetic adaptations (e.g., H5N1) ([@bib0116]); and these vaccines can cause strong allergic reactions in some individuals. Live, attenuated influenza vaccines have the advantage of inducing secretory and systemic immunity and are applied intranasally, preventing virus replication in the respiratory tracts ([@bib0055]). However, all of these vaccines still need to be grown in chicken embryos, which are ironically also the target for a potentially pandemic virus like H5N1.

To overcome these drawbacks, various cell‐based vaccines for influenza are under development as well as recombinant protein vaccines. Clinical trials of vaccines based on influenza virus produced in mammalian cell cultures, such as Madin Darby canine kidney (MDCK) cells, have been described ([@bib0028], [@bib0212]) and trials with influenza vaccines produced in the human retina cell line Per.C6^®^ ([@bib0207]) are ongoing. These products still require inactivation of the influenza virus which may reduce immunogenicity as seen for inactivated vaccines. In response to human casualties of H5 and H7 influenza viruses in Asia in the late 1990s, the immunogenicity and safety of baculovirus recombinant H5 and H7 hemagglutinin (HA) proteins was tested in chickens and resulted in 100% protection against disease symptoms ([@bib0056]). The immunogenicity of the baculovirus‐derived H5 vaccine was subsequently evaluated in over 200 healthy human adults. The vaccine was well tolerated and provided neutralizing antibody responses equivalent to those observed in convalescent sera in ∼50% of the individuals after two doses ([@bib0282]). A clinical trial with baculovirus‐produced recombinant H3 antigens in 127 adult volunteers showed protective neutralizing antibody levels and a reduction in influenza rates in the following epidemic season compared to a placebo group ([@bib0226]). This HA‐based vaccine induced both B and T memory cells ([@bib0227]). A clinical study of 399 individuals with an average age of 70 years was completed in 2003--2004 with an experimental vaccine (FluBlØk, Protein Sciences corporation) containing the same three HA antigen variants as present in the licensed inactivated vaccine of that flu season ([@bib0283]). Compared to the licensed vaccine, the recombinant vaccine produced higher antibody titers against the H3 strain, the strain responsible for the majority of influenza deaths each year ([@bib0054]). This result suggests that this vaccine can be especially useful for reduction of the annual number of influenza‐related deaths in the elderly, where H3 antibody titers induced by conventional vaccines are too low to be protective. Phase III trials in healthy adults have been completed and showed a 100% protective effcicacy even against H3N2 influenza viruses (Manon Cox, personal communication) (<http://www.proteinsciences.com/>, Jan 2006). Preparation of a recombinant influenza virus vaccine cocktail for the coming flu season may take about 3 months to complete from the moment the new vaccine composition is announced by the World Health Organization (WHO).

The inactivated conventional vaccine and the trivalent recombinant HA‐based vaccine under development are based on antibody responses against the HA surface protein and require annual modifications to the vaccine due to antigenic drift of the influenza virus. A baculovirus recombinant vaccine with both HA and neuraminidase (NA) subunits resulted in a bivalent seroconversion with antibodies against both HA and NA ([@bib0130]). The efficacy of an H3N2 vaccine based on both HA and NA produced with a recombinant baculovirus was analyzed in a murine model and compared with a conventional killed and a live‐attenuated vaccine preparation and an HA single‐subunit vaccine ([@bib0030]). The NA in the baculovirus‐derived vaccine was much more immunogenic than in the conventional vaccines. The advantage of inducing an immune response to both surface proteins is illustrated by the fact that the recombinant vaccine containing both HA and NA did not only prevent infection with homotypic and closely related viruses, but also showed a strong reduction in pulmonary virus titers in infections with a more distantly related virus (H3N2 A/Panama/2007/99 versus A/Fuijan/411/2002), in contrast to a vaccine based on HA only. These results suggest that a vaccine containing intact NA tolerates more antigenic drift, thereby reducing the chance of virus escaping the immune system during the flu season.

B. Virus‐like Particles {#sec0010}
-----------------------

Viral capsid proteins produced in insect cells often self‐assemble into VLPs. The advantage of VLPs is that they resemble the natural virus but are not infectious because they lack genetic material. VLPs are also an excellent tool for study of virus structure. VLPs can easily be purified by extraction, centrifugation, or precipitation ([@bib0035]) and often give strong immune reactions even in the absence of adjuvants due to their particulate nature. In addition, humoral, cell‐mediated, and mucosal immune responses have been reported ([@bib0237]). An example of a vaccine consisting of recombinant VLPs produced with a baculovirus vector is a patented *Canine parvovirus* vaccine ([@bib0169], [@bib0286]). Sometimes the expression of more than one viral coat protein is needed to make immunogenic VLPs, either due to the complexity of the capsid structure (*Bluetongue virus*: BTV, *Reoviridae*) or presence of crucial epitopes on several coat proteins. Multicomponent VLPs can be produced by using vectors with multiple promoters or by coinfections with several baculovirus vectors that each encode one or more viral proteins. One difficulty in making complex VLPs is to achieve appropriate expression levels of each protein present in the viral capsid.

The capsid protein of *Hepatitis E virus* (*Caliciviridae*) forms VLPs and these VLPs induce both systemic and mucosal immunity after oral administration in a mouse model. They also protect cynomolgus monkeys when challenged with HEV against infection and hepatitis ([@bib0164], [@bib0165]). Infectious bursal disease (IBDV, *Birnaviridae*) of birds can also be prevented by vaccination with single component VLPs ([@bib0183], [@bib0304]). The major capsid protein L1 of *Papovaviridae* forms VLPs and has been shown to protect cottontail rabbits against *Cottontail rabbit papillomavirus*. Combinations of the HPV‐16 L1 and L2 capsid proteins and the oncogenic protein E7 protected against tumor formation in a mouse model ([@bib0096]). Multivalent VLP preparations containing BTV (*Reoviridae*) VP2 subunits of various serotypes were made by coinfections of several baculovirus vectors and induced long‐lasting protection in sheep ([@bib0240]). Vaccine candidates in the form of VLPs with up to four different VPs have also been successfully produced for BTV ([@bib0208], [@bib0289]) as well as for several other *Reoviridae* ([@bib0049], [@bib0050]). Immunization of mice with an influenza VLP containing the two matrix proteins M1 and M2, and the surface proteins HA and NA showed almost complete protection against an H3N2 virus via both intramuscular and intranasal immunization routes ([@bib0081]).

The rationale for using VLPs as vaccine candidates is obvious for nonenveloped viruses, because in these viruses the capsid proteins are directly exposed to the immune system. However, they may also be useful for displaying epitopes of enveloped viruses. HIV is an enveloped virus and in this case VLPs have been produced based on gp55 (gag) to which immunogenic segments of the envelope protein gp120 were coupled ([@bib0008], [@bib0037], [@bib0278]). An extension of these chimeric VLP‐based vaccines is to use VLPs of one virus to display epitopes of heterologous proteins that do not form VLPs by themselves. Examples of such systems are *Human parvovirus B19* VLPs which carry linear epitopes in fusion with the viral VP2 protein. This system was used to display epitopes of *Murine hepatitis virus* A59 (MHV; *Coronaviridae*) and Herpes simplex virus (HSV; *Herpesviridae*) ([@bib0036]). Such chimeric VLPs protected mice against a lethal challenge with MHV of HSV. Epitope‐presenting chimeric VLPs have also been developed based on *Mouse papillomavirus* ([@bib0273]) and *Flock house virus* VLPs ([@bib0252]).

C. Inclusion of Recombinant Cytokines in the Vaccine {#sec0011}
----------------------------------------------------

Mono‐ and oligomeric protein subunits are often less potent and need to be formulated carefully before administration to extend their half‐life and to present them in a proper form to the immune system, for instance by uptake by antigen‐presenting cells (APCs) ([@bib0065], [@bib0248]). Adjuvant possibilities for human application are very limited because of safety considerations and this may limit the application of monomeric subunit vaccines in humans. VLPs on the other hand have been shown to induce protection even without the addition of adjuvants ([@bib0165], [@bib0237]). An alternative way to modulate the immune response is by the addition of recombinant cytokines as vaccine adjuvants. Cytokines can either be added separately to the vaccine or may be included in VLPs. This approach may not only modulate the magnitude but also the type of immune response ([@bib0167]). By carefully choosing which cytokine is added the immune response can be driven in a certain direction. Interferon gamma (IFN‐γ) may be added to stimulate macrophages, while addition of interleukin‐12 (IL‐12) promotes cell‐mediated adaptive immunity ([@bib0001]). IL‐12 can be efficiently produced with baculovirus vectors as functional dimers that shift the immunogenic balance to Th1 cells in bovine calves ([@bib0268]). IL‐12 added to influenza VLPs enhances antibody responses but in this case VLPs alone already result in 100% protection ([@bib0081]). Immune reactions to helminths involve Th2 responses. Interleukin‐4 (IL‐4) drives the immune response to differentiation of Th2 cells and to the production of heminth‐specific IgE antibodies ([@bib0001]). Addition of IL‐4 may therefore be helpful for vaccines against helminths ([@bib0167]). For baculovirus‐derived products the addition of cytokines has not been fully exploited, but it is commonly used for DNA vaccines. The addition of costimulators, such as B7 or CD40, to baculovirus‐produced vaccines has not been reported.

D. Baculoviruses as DNA Vaccines {#sec0012}
--------------------------------

Baculoviral vectors with mammalian promoters driving the expression of viral genes have been used in a limited number of vaccine trials. A candidate *Pseudorabies virus* vaccine expressing its glycoprotein B from a recombinant baculovirus vector with a mammalian promoter resulted in seroconversion in immunized mice ([@bib0007]). Intramuscular injection with baculovirus BVs expressing the E2 glycoprotein of *Hepatitis C virus* controlled by the CMV immediate‐early promoter‐enhancer provided specific humoral and cellular responses ([@bib0072]). Similar results were obtained with the carcinoembryonic antigen (CEA) indicating that these types of vaccines can also be effective against tumors. The addition of the *Vesicular stomatis virus* (VSV) G protein to the baculovirus envelope increased immunogenicity in this experiment, possibly by enhancement of virus fusion. BacMam™ vectors have also been used to produce mutated, attenuated influenza virus in mammalian cells by delivery of an altered *NS1* gene ([@bib0224]). Surprisingly, a baculovirus vector with the influenza hemagglutinin gene (*H1*) controlled by the chicken beta‐actin promoter gave a similar level of protection as a wild‐type baculovirus against a lethal influenza challenge in intranasally immunized mice ([@bib0002]). The authors ascribe this to the induction of a strong innate immune response by the baculovirus, protecting the mice from a subsequent lethal challenge with influenza virus.

A possible drawback to the use of baculoviruses directly for vaccination and possibly also for surface display and polyhedra‐incorporation vectors is the accumulation of anti‐baculovirus antibodies upon repeated vaccination, resulting in rapid inactivation of subsequent vaccines of the same type. Pigs for instance have been shown to produce high levels of baculovirus‐neutralizing antibodies after injection of baculovirus BVs ([@bib0284]). A solution to this problem could be to design multivalent vaccines, since baculoviruses can take up a large amount of foreign DNA. Another problem with the use of baculovirus particles as vaccines is rapid degradation by the complement system which also affects gene therapy applications. Pseudotyping of BVs with the VSV glycoprotein instead of GP64 resulted in a reduction in complement inactivation ([@bib0270]). Incorporation of human decay‐accelerating factor (DAF), a complement‐regulatory protein, in the BV envelope has been shown to protect baculovirus gene therapy vectors against complement‐mediated inactivation ([@bib0122]). This strategy could also be applied for vaccine purposes.

E. Combinations of Vaccine Strategies {#sec0013}
-------------------------------------

HIV VLPs containing only gp55 (gag) have been used to boost immunization induced by a gp55 DNA vaccine ([@bib0126]). In this case, a capsid protein of an enveloped virus is a reasonable subunit for vaccination because DNA vaccines are expressed intracellularly and fragments of the resulting proteins are presented by MHC complexes to induce cellular immune responses. In this way the natural situation of intracellular expression of viral genes is mimicked. T cell responses, especially the action of cytotoxic T lymphocytes (CTL) are crucial in defense against HIV. HIV combination vaccines where adenovirus, vaccinia (HIVAC‐1e), or vesicular stomatitis virus vectors were used for immunization in combination with a boost with a protein subunit (gp160, gp41) have been tested in phase I trials in humans ([@bib0052], [@bib0095], [@bib0171], [@bib0175], [@bib0211], [@bib0322]). Viral carriers also express HIV antigens inside cells, and these antigens are displayed either by specialized APCs or other cells to the immune system. The aim of this regimen with a DNA/carrier vaccine and a protein boost regimen is therefore to induce both neutralizing antibodies and T cell responses.

F. Viral Marker Vaccines and Differential Diagnosis Technology {#sec0014}
--------------------------------------------------------------

Nonvaccination policies exist for many animal diseases because of the risk that vaccinated animals may be protected against disease but may still be carriers of the virus. In cases of outbreaks, ring vaccination is sometimes applied, but large‐scale vaccination is generally not allowed. A prerequisite for the broader use of animal vaccines is the development of marker vaccines that enable differentiation between vaccinated and infected animals. This is especially important for endemic diseases in animals where monitoring is of crucial importance to avoid spread of the virus to nonendemic regions or to other host species such as humans or wild animals. Marker vaccines also have good prospects for eradication of animal diseases in general ([@bib0288]). For such purposes, marker vaccines do not have to give 100% herd immunity, because reducing susceptibility and transmission can be sufficient to have a major effect in controlling animal disease ([@bib0107]). Marker vaccines need to be accompanied by specific diagnostic tests that are commonly based on determining serum titers of a viral component that is absent in the vaccine but present in the pathogen, to which antibodies can be raised.

The baculovirus expression system has proven to be useful in producing not only the protein subunits for marker vaccines but also the recombinant polypeptides for these diagnostic tests. The commercially available CSFV vaccine based on the E2 glycoprotein is a marker vaccine because only antibodies against E2 are generated. An enzyme‐linked immunosorbent assay (ELISA) test for serum antibodies against the other immunogenic surface protein E^RNS^ can be used to discriminate immunized animals from virus carriers ([@bib0158], [@bib0288]). Another possibility is to use only some of the epitopes of an antigen for immunization and others for the diagnostic analysis, as demonstrated for CSFV ([@bib0295]). The coexistence of a subunit vaccine and a discriminative diagnostic test enabled registration of CSFV vaccines in Europe. Marker vaccines will also be very useful for immunization of poultry against avian influenza ([@bib0056]), where monitoring for the presence of virus is essential. Animals immunized with HA or HA/NA vaccines could be screened for antibodies against the viral matrix proteins. Similar assays have been developed for other subunit vaccines, such as one that discriminates between VSV‐infected and immunized animals, where the marker vaccine is based on the glycoprotein and the assay on the nucleocapsid protein produced in insect larvae ([@bib0003]).

IV. Baculovirus‐Produced Vaccines Against Protozoan Parasites and Helminths {#sec0015}
===========================================================================

Parasites of the genera *Plasmodium, Theileria,* and *Babesia* are protozoan blood parasites causing malaria, theileriosis, and babesiosis. These parasites have a complex life cycle and are transmitted by either mosquito or tick vectors. Candidate subunit vaccines against these parasites can be roughly separated into preblood (preerythrocyte or prelymphocyte) stage vaccines, blood stage vaccines, transmission‐blocking vaccines, and multistage vaccines. An overview of parasite subunits expressed in the baculovirus insect cell system for vaccine purposes is given in [Table IV](#tbl0004){ref-type="table"} .Table IVVaccine Trials for Parasitic Diseases Based on Subunits Expressed in the Baculovirus--Insect Cell SystemPathogenAntigenTrialImmunologic responseReferencesProtozoa*Babesia rodhaini*P26 surface proteinImmunization of rats40--100% protection[@bib0123]*Plasmodium berghei*Ookinete surface protein 21Injection in miceAntibodies, oocyst formation blocked in *Anopheles stephensi* mosquitoes[@bib0184]*Plasmodium cynmolgi*Merozoite surface protein (MSP)‐1Challenge in primatesProtection[@bib0213]*Plasmodium falciparum*Circumsporozoite protein (CSP)Human safety and immunity trialNo response to native CSP[@bib0108]*Theileria parva*Sporozoite surface protein p67Challenge in cattle50% protection[@bib0193]Sporozoite surface protein P67 (GFp fusion, surface display)Challenge in cattleUpto 80% protection[@bib0135], [@bib0136]*Theileria sergenti*P32Challenge in cattleProtection[@bib0201]*Trypanosoma cruzi*TolTMice immunization/*in vitro* inhibition by CD4 cells50--60% reduction of parasite numbers in infected macrophages[@bib0231]Helminths*Fasciola hepatica*Procathepsin L3Challenge in rats50% protection[@bib0058]*Ostertagia ostertagi*Metalloprotease 1Challenge in cattleNo protection[@bib0060]Aspartyl‐protease inhibitorChallenge in cattleNo protection[@bib0061]*Schistosoma mansoni*Calpain (Sm‐p80)Challenge in mice29--39% reduction in worms[@bib0117]

A. Plasmodium {#sec0016}
-------------

A comprehensive record of all subunit and recombinant carrier vaccines under development for human malaria is maintained by WHO ([@bib0233]). Most of these vaccines are still in a preclinical stage but several *Plasmodium falciparum* vaccines are in phase I and phase II trials in malaria endemic countries. *Plasmodium* is transmitted in the form of sporozoites by *Anopheles* mosquitoes. A vaccine candidate based on the circumsporozoite protein (CSP) is aimed at blocking these sporozoites. Both B and T cell responses appear to be essential for protective immunity based on the CSP protein. CSP has been produced in insect cells but was minimally immunogenic when tested in 20 volunteers ([@bib0108]). Alternative approaches to experimental CSP vaccines, which facilitate T cell responses, are in phase II trials ([@bib0015]). These vaccines include CSP displayed on HBsAg VLP particles, modified vaccinia Ankara virus as recombinant carrier, or DNA vaccines.

The merozoite is the extracellular, erythrocyte‐invasive form of the *Plasmodium* parasite. Merozoite surface proteins are promising vaccine candidates due to their accessibility for antibodies and their expected role in erythrocyte invasion. The major merozoite surface protein (MSP‐1) is an important prebloodstage candidate vaccine with homology to epidermal growth factor (EGF) and antibodies directed against this protein block erythrocyte invasion ([@bib0112]). *Plasmodium cynomolgi* functions as a model system for the highly similar *Plasmodium vivax* in humans. An active, C‐terminally processed form of *P. cynomolgi* MSP‐1, was produced in insect cells and protected primates in a challenge experiment ([@bib0213]). The C‐terminally mature MSP‐1 of *P. falciparum* was also successfully expressed in insect cells and used for ultrastructural studies ([@bib0043], [@bib0222]), but has not been tested in human trials. Meanwhile, *E. coli*‐expressed MSP‐1 has entered phase II clinical trials ([@bib0015]).

*Plasmodium* parasites in the ookinete stage are taken up by mosquitoes and antigens specific for this stage can function as transmission‐blocking subunit vaccines. The major ookinete surface antigen Pbs21 (P28) of *Plasmodium berghei* was expressed in *B. mori* larvae, preserving conformational B cell epitopes which were lost upon expression in *E. coli*. The recombinant Pbs21 antigen produced in insect cells blocked oocyte formation in *Anopheles* mosquitoes fed on immunized mice ([@bib0184]). The immunogenicity of the recombinant protein was strongly reduced when the protein was expressed as a secreted protein by removing its glycosylphosphatidylinositol (GPI) anchor signal ([@bib0181]). This protein provides a good example of loss of immunogenicity by expressing a membrane protein in a secreted form. Subunit vaccines based on the *Plasmodium*‐induced erythrocyte membrane protein 1 (EMP‐1) are aimed at blocking vertical transmission from mother to child (maternal malaria) via the placenta. This transmission involves the sequestration of *P. falciparum*‐infected erythrocytes through EMP‐1, which binds to chondroitin sulphate A in the placenta. EMP‐1 expressed in the baculovirus system induces inhibitory antibodies which react with both homologous and heterologous EMP‐1 proteins ([@bib0053]).

B. Theileria *and* Babesia {#sec0017}
--------------------------

*T. parva* is the causative agent of East Coast fever, a deadly cattle disease endemic in large parts of Africa. Immunization with recombinant sporozoite surface protein p67 is aimed at blocking invasion of lymphocytes by this parasite. P67 is an example of a protein that was not easy to express in a native form in insect cells as well as in many other systems. In insect cells, it was expressed at low levels and in contrast to expectations was not present on the cell surface. Similar to *E. coli*‐expressed p67, it did not react with a monoclonal antibody against native p67, indicating that the folding of the protein was not correct ([@bib0193]). Several adaptations were therefore made to the expression system. Expression of p67 coupled to the honeybee mellitin signal instead of the original signal peptide resulted in correct routing of this protein to the cell surface, but the folding was still not optimal ([@bib0134]). Fusion of p67 to the C terminus of GFP drastically increased expression levels and resulted in recognition by the conformation‐sensitive monoclonal antibody ([@bib0132]). A similar effect was also seen when parts of this protein were fused to the baculovirus GP64 glycoprotein in a surface display vector, which led to expression on the cell surface and on baculovirus BVs ([@bib0133]). The recombinant GFP‐p67 protein and the C terminal half of p67 coupled to GP64 induced high levels of sporozoite‐neutralizing serum antibodies and showed up to 80% protection against lethal *T. parva* challenge in a double‐blind placebo‐controlled experiment ([@bib0135], [@bib0136]). The next phase will be to evaluate the quality of these experimental vaccines under field conditions in countries in which East Coast fever is endemic.

*Babesia* species are a major cause of parasitemias in cattle and dogs. *Babesia divergens* is the major cause of bovine babesiosis in Europe and the increased incidence of this disease is correlated with an increase in the numbers of ticks (*Ixodus ricinus*) that transmit this parasite. *B. divergens* is also responsible for zoonotics in immunocompromised humans ([@bib0323]). The soluble parasite antigen (SPA) of bovine and canine *Babesia* species has been developed as a vaccine against clinical manifestations in dogs and is produced in mammalian cells infected with *Babesia* ([@bib0247]). Several other *Babesia* antigens have been expressed in the baculovirus expression system to develop ELISA tests for diagnosis. The baculovirus‐expressed *Babesia radhaini* P26 protein was shown to induce protection against the disease in rats ([@bib0123]).

*Theileria* and *Babesia* parasites are transmitted by ioxidic ticks and in the future candidate antiparasite vaccines may be combined with vaccines directed against the tick vector ([@bib0021]). These vaccines may be tick antigens directly exposed to the host immune system, such as vitellin, the most abundant *B. microplus* egg protein ([@bib0274]) or cement proteins involved in the attachment of the tick to the skin of the host. Concealed antigens can also give good results, such as the *B. microplus* Bm86 gut antigen (Gavac™), which results in binding of antibodies taken up from immunized animals to a gut transmembrane protein ([@bib0311]). Ticks are known to immunomodulate their host by secreting specific immunomodulators and transmitted parasites also profit from the reduction in immune response. Tick vaccines may therefore be aimed at reducing the chance of transmission by directly affecting the feeding process, by interacting with immunomodulators, or by reducing tick populations.

C. Trypanosoma *and* Leishmania {#sec0018}
-------------------------------

Chagas' disease in the Americas is caused by *Trypanosoma cruzi* and is found in humans, dogs, cats, and rodents. *T. cruzi* is a macrophage‐invading protozoan, and complicating factors in the development of vaccines are immune escape and autoimmunity due to molecular mimickry ([@bib0090]). Macrophages are also the target for *Leishmania* parasites, which use complex immune evasion strategies that affect host cell signaling ([@bib0199]). Immunization with the *T. cruzi* Tol A‐like protein (TolT) expressed in insect cells resulted in T cell‐dependent antiparasitic activity ([@bib0231]). For *Leishmania* several candidate subunit vaccine antigens with protective potential have been identified, including the surface protein gp63 ([@bib0048]), but these proteins have not been expressed with baculovirus vectors in insect cells.

D. Helminths {#sec0019}
------------

Helminths or parasitic worms that are a serious threat to human and animal health worldwide, are divided into the Annelida (segmented worms), Platyhelminthes (flatworms including flukes), and Nematoda (roundworms). These worms have complex life cycles, which often involve more than one host. Because helminths vary widely among populations, vaccines are not competitive so far with chemical broad spectrum antihelminths ([@bib0025]). Helminths may also modulate the immune system as exemplified by the filarial nematodes, which are present in 150--200 million humans worldwide and cause river blindness for example. These filarial nematodes are difficult to combat because they modulate T cell responses leading to chronic helminth infections (reviewed by [@bib0110]). This T cell modulation is not restricted to the response to filarial larvae but also affects allergies, the response to other pathogens and vaccines through modulation of not only antigen‐specific T cells but also APCs, which affects immune responses in general.

There are a few examples of baculovirus‐expressed helminth proteins but few of these have been tested in immunization studies ([Table IV](#tbl0004){ref-type="table"}). However, the baculovirus expression system may be a valuable tool for these parasitic worms as illustrated by the following examples: a baculovirus‐derived subunit vaccine against liver fluke (*Fasciola hepatica*) based on procathepsin L3 conferred 50% protection to rats, in contrast to the yeast‐expressed protein which did not confer any protection ([@bib9004]). Bilharzia or schistosomiasis is caused by *Schistosoma* spp. (Platyhelminthes), blood parasites of humans in tropical areas. Several *Schistosoma* genes have been expressed in insect cells, but primarily for analysis of enzymatic functions. The large subunit of calpain (SmP80) produced in the baculovirus expression system reduced the worm burden in mice ([@bib0117]). Antigens of the tapeworm *Taenia solium* have been expressed with baculovirus vectors for diagnostic purposes ([@bib0160], [@bib0163]).

V. Conclusions and Prospects {#sec0020}
============================

There are many examples in the literature where immunization with recombinant proteins produced in the baculovirus--insect cell expression system conferred good protection against infectious disease. Subunit vaccine development begins with careful identification of the antigen, which is related to whether neutralizing adaptive immune responses are raised against the particular protein in natural infections. Once selected, the open reading frame (ORF) of the antigen is cloned while keeping flanking DNA sequences to a minimum, which can best be achieved with a proof‐reading PCR enzyme. The sequence around the ATG translational start site is best modified to that of the polyhedrin or p10 gene in the wild‐type baculovirus, with at least an adenosine residue at the −3 position ([@bib0042]). Tags may be added to facilitate purification, preferably in such a way that they can subsequently be removed. Tags are not required for VLPs because they can be purified by centrifugation. Transmembrane (glyco)proteins are best produced in a secreted form by removal of TMRs to increase expression levels. However, this may occasionally affect the folding of the protein. An alternative approach is to fuse the immunogenic domains of envelope proteins to GP64. Vectors that lack chitinase and v‐cathepsin genes are preferable for expression of envelope proteins. During the preparation of seed stocks, care should be taken to keep the virus passage number low and to use a multiplicity of infection of \<0.1 to minimize the formation of DIs. Careful checking of the purity of recombinant bacmids or plaque purified recombinant viruses by PCR is crucial to avoid loss of recombinant virus in subsequent passages due to empty vectors that out‐compete the recombinants.

Only two baculovirus‐produced products are approved for veterinary practice, namely, two vaccines against classical swine fever consisting of the E2 surface glycoprotein. With these vaccines in the market (although a nonvaccination policy still exists) the confidence in this type of subunit vaccine will grow as well as the possibilities for registration, thereby increasing the likelihood that more vaccines of this kind will appear in the market. This expectation of an increasing number of products may be expanded to human applications when registration of a trivalent recombinant influenza vaccine, for which phase III clinical trials in humans in the United States have been completed recently, can be achieved. Therapeutic anticancer vaccines, such as a vaccine against prostate cancer, may be more readily accepted, in view of the severe side effects of anticancer drugs and irradiation techniques. The application of baculovirus display or BacMam™ vectors for vaccines against infectious disease may be applied in the future for animal use. Because more foreign proteins are incorporated into the vaccine than just the targeted antigen, such vaccines for human use are likely to be in the more distant future because of safety considerations.

Baculovirus expression systems compete with other cheaper production systems, which are more widely used and which scale‐up more easily, such as *E. coli* and yeast ([Table I](#tbl0001){ref-type="table"}), and once a good protection level is achieved there is no commercial interest to switch to the more expensive insect cell system. For those cases though, where folding or posttranslational modifications are crucial to epitope formation the baculovirus--insect cell system is a versatile expression system and many candidate vaccines have been successfully tested. Alternative methods are provided by the development of DNA vaccine technology and recombinant carrier vaccines based on vaccinia, adenovirus, or BacMam™ vectors ([Table II](#tbl0002){ref-type="table"}). These methods are more prone to induce cellular immune responses than many protein subunit vaccines. The combination of a primary vaccine with an intracellular delivery system (recombinant carrier vaccines, DNA vaccines, BacMam™ vectors) followed by a boost immunization with recombinant protein subunits appears to be a promising approach, aimed at both cellular and humoral immune responses. This approach can be further strengthened through the addition of recombinant cytokines that drive the immune response in a specific direction. A major challenge now is to broaden the array of viral vaccines produced in insect cells and to develop effective vaccines against more complex organisms, such as protozoan parasites and multicellular worms, for which the baculovirus expression system also holds promise. With the increasing insight into immunology leading to new methods of vaccine production and delivery, accompanied by a wealth of genomic and proteomic data, many new generation vaccines are expected within the foreseeable future.
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[^1]: Adapted from [@bib0300].

[^2]: [@bib0083], [@bib0243], [@bib0319]; Universal data base of International Committee on Virus Taxonomy (<http://www.ncbi.nlm.nih.gov/ICTVdb/index.htm>; January 2006).

[^3]: AcMNPV, *Autographa californica* multiple nucleopolyhedrovirus.

[^4]: Dashes in the table mean not analysed in this study.

[^5]: Only those antigens are included that were tested in immunization experiments.

[^6]: If not known whether neutralizing indicated as "antibodies."

[^7]: VLP, virus‐like particle.

[^8]: ADE, antibody‐dependent enhancement by nonneutralizing antibodies (resulting in chronic infections).

[^9]: MEPR, membrane‐proximal region.

[^10]: PERV, porcine endogenous retrovirus.

[^11]: Boost, boost with baculovirus‐produced recombinant protein, prime form other origin.
